Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.60 |
| ▸ | HTR2A | P28223 | 14/20 | 0.60 |
| ▸ | HTR1A | P08908 | 11/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4253960 | 0.99 | DRD2 (0.60) | DRD2HTR2AHTR1AHTR7HTR2B | |
| SCHEMBL4261632 | 0.93 | DRD2 (0.59) | DRD2HTR2AHTR1AHTR7HTR2B | |
| Hydrochloric Acid SCHEMBL4255247 | 0.92 | DRD2 (0.58) | DRD2HTR2AHTR1AHTR7HTR2B | |
| SCHEMBL8153404 | 0.87 | USP2 (0.54) | DRD2HTR2AHTR1AHTR7USP2 | |
| SCHEMBL4253499 | 0.80 | DRD2 (0.61) | DRD2HTR2AHTR1AHTR7MCHR1 | |
| SCHEMBL4253491 | 0.79 | HTT (0.66) | USP2HTT | |
| Hydrochloric Acid SCHEMBL4257351 | 0.79 | DRD2 (0.61) | DRD2HTR2AHTR1AHTR7MCHR1 | |
| SCHEMBL826886 | 0.77 | DRD2 (0.62) | DRD2HTR2AHTR1AHTR7HTR2B | |
| SCHEMBL1042536 | 0.76 | DRD2 (0.59) | DRD2HTR2AHTR1AHTR7HTR2B | |
| Brilaroxazine SCHEMBL3404085 | 0.76 | DRD2 (1.00) | DRD2HTR2AHTR1AHTR7HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207163-B2 | Compositions, synthesis, and methods of using piperazine based antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | GRIK5, GAP43, GRIN2D | DRD2 33/4885HTR2A 41/4885HTR1A 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.